Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

The Ndovu RCT is studying the best treatment strategy for people living with HIV whose virus has developed resistance to a first-line medication called dolutegravir. The study is comparing different antiretroviral drug combinations to find the most effective approach when resistance develops. **You may be eligible if...** - You are at least 3 years old - You are already enrolled in the Ndovu cohort study - Your HIV viral load is 200 copies/mL or higher (meaning the virus is not fully suppressed) - Your HIV has developed at least one specific resistance mutation to dolutegravir - You are able to provide informed consent (or a guardian can consent for you) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are taking medications that cannot be safely combined with the study drugs - You have a serious active HIV-related illness (WHO stage 3 or 4) that would prevent you from being assigned to either treatment arm Talk to your doctor to see if this trial is right for you.